Vaxart, Inc. (VXRT) Debt Components
- 2019-09-30: Notes Payable, CurrentUSD (m); Notes PayableUSD $2.50M; Long-term DebtUSD (m); Debt Instrument, Interest Rate, Stated Percentagepure (m).
- 2019-06-30: Notes Payable, CurrentUSD (m); Notes PayableUSD $2.80M; Long-term DebtUSD (m); Debt Instrument, Interest Rate, Stated Percentagepure (m).
- 2019-03-31: Notes Payable, CurrentUSD (m); Notes PayableUSD $3.20M; Long-term DebtUSD (m); Debt Instrument, Interest Rate, Stated Percentagepure (m).
- 2018-12-31: Notes Payable, CurrentUSD (m); Notes PayableUSD (m); Long-term DebtUSD $17.74M; Debt Instrument, Interest Rate, Stated Percentagepure 8.00%.
Vaxart, Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Notes Payable, Current USD | Notes Payable USD | Long-term Debt USD | Debt Instrument, Interest Rate, Stated Percentage pure | Debt Instrument, Convertible, Conversion Price USD/shares | Debt Instrument, Increase, Accrued Interest USD | Debt Instrument, Unamortized Discount USD | Notes Payable, Related Parties, Current USD | Notes Payable, Related Parties, Noncurrent USD |
|---|---|---|---|---|---|---|---|---|---|
| 2019-09-30 | (m) | $2.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $2.80M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $3.20M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | $17.74M | 8.00% | (m) | (m) | $300.00K | (m) | (m) |
| 2018-09-30 | $102.00K | (m) | $17.58M | 8.00% | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $153.00K | (m) | $17.07M | 8.00% | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $214.00K | (m) | (m) | 8.00% | (m) | (m) | (m) | $1.67M | $3.07M |
| 2018-03-30 | (m) | (m) | $16.60M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-02-13 | (m) | (m) | (m) | (m) | 9.05 | (m) | (m) | (m) | (m) |
| 2018-02-13 | (m) | (m) | (m) | (m) | (m) | (m) | $400.00K | (m) | (m) |
| 2018-02-12 | (m) | (m) | $16.30M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | $15.90M | (m) | (m) | (m) | $2.50M | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | 12 month · $6.30M | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.53M | $3.44M |
| 2017-12-31 | $300.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $200.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $200.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $300.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $300.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $400.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $400.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $500.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $400.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $200.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $200.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |